Author's posts
Sharing of real world data, getting patients involved, is needed for better pharma collaborations
Pharma wants to be a part of value-based programs in risk-based arrangements with payers.
Spending money on the social determinants is an investment
Value-based care demands the switch to wellcare to raise outcomes and decrease costs, Claire Pomeroy says.
High drug prices: Who’s really to blame?
How telehealth can answer demand for behavioral health services
Mental health services accounted for 31 percent of all diagnoses associated with telehealth claims in 2016, according to FAIR Health.
Over 96 percent of health systems plan to expand virtual care, new survey shows
Data shows slow industry adoption, as close to 42 percent of respondents said their virtual care solution did not integrate with their EHR.
Easing time spent on prior authorization requires industry-wide adoption of electronic transactions
HIMSS19: Leveraging technology to improve prior authorization…
NYU Langone tackles end-of-life care decision-making
NYU Langone embedded a provider-facing screening question into the EHR admission process that was cosigned on admission and at discharge by the attendant of record.
Atul Gawande’s company looking to try new products on employees, trial testimony shows
Plans are for the 1.2 million employees of Amazon, Berkshire Hathaway and JPMorgan Chase, with no current intent to sell to broader market.
Democrats, America’s Health Insurance Plans, denounce HHS plan targeting drug rebates
Community Oncology Alliance commends proposal to overhaul what it calls secretive drug rebate system that drives list prices higher.
Health and Human Services wants to end ‘middlemen kickbacks’ in drug pricing by targeting rebates
Under the proposal, drugs would be chosen that have the lowest price, not the ones that offer the highest rebate.
